Mathematical modeling of canonical and non-canonical NF-kappa B pathways in TNF stimulation
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
Authors: Ji, Bing; Zhang, Yao; Zhen, Changqing; Fagan, Michael J.; Yang, Qing
Abstract
Background and objective: NF-kappa B can be activated by the canonical and non-canonical pathways. These two pathways interplay via the TRAF1 vertical bar NIK complex after stimulation by TNF. However existing mathematical models of two pathways are inadequate. In this context, an improved mathematical model is constructed to simulate these two pathways and their coupling stimulated by TNF. Methods: A schematic description of two NF-kappa B pathways and their relation after TNF stimulation is constructed at first. Then twenty-eight ordinary differential equations are utilized to build the mathematical model. Model equations are solved via the ordinary differential equation solver (ode23). Results: The proposed model firstly reconstructs the changes in concentrations of NF-kappa B pathway related biochemical factors with time, and further investigates the underlying mechanism of interaction between two pathways through the TRAF1 vertical bar NIK complex after stimulation. Conclusions: The model is validated through good agreement between simulation results and published experimental observations. This study helps to well understand the canonical and non-canonical pathways and their interaction. It also provides a potential tool to investigate how the dysregulated pathways act in pathological conditions. (C) 2020 Elsevier B.V. All rights reserved.
Protease-activated receptor 4 plays a role in lipopolysaccharide-induced inflammatory mechanisms in murine macrophages
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Authors: Barra, A.; Freitas, K. M.; Marconato, D. G.; Faria-Pinto, P.; Lopes, M. T. P.; Klein, Andre
Abstract
The role of protease-activated receptor (PAR)4 in thrombin-induced platelet aggregation has been studied, and PAR4 blockade is thought to be useful as a new and promising approach in antiplatelet therapy in humans. In recent years, studies have been conducted to clarify the role of PAR4 in the host defense against invading microorganisms and pathogen-induced inflammation; however, to date, the role of PAR4 in mediating the LPS-induced inflammatory repertoire in macrophages remains to be elucidated. Here, we investigated the effects of the synthetic PAR4 agonist peptide (PAR4-AP) AYPGKF-NH2 on the phagocytosis of zymosan-FITC particles; NO, ROS, and iNOS expression; and cytokine production in C57/BL6 macrophages cocultured with PAR4-AP/LPS. The PAR4-AP impaired LPS-induced and basal phagocytosis, which was restored by pharmacological PAR4 blockade. Coincubation with the PAR4-AP/LPS enhanced NO and ROS production and iNOS expression; decreased IL-10, but not TNF-alpha, in the culture supernatant; and increased translocation of the p65 subunit of the proinflammatory gene transcription factor NF-kappa-B. Our results provide evidence for a complex mechanism and new approach by which PAR4 mediates the macrophage response triggered by LPS through counter-regulating the phagocytic activity of macrophages and innate response mechanisms implicated in the killing of invading pathogens.